Member Info for LiveLongnProsper

Good to see @RAH00084 on LSE as well as Twit.
Discussion about Clovis interesting.
The Clovis competitor analysis from their end-2021 SEC filing maybe of interest to LTH’s …
https://www.sec.gov/Archives/edgar/data/0001466301/000155837022001810/clvs-20211231x10k.htm
Radioligand competition starts with (our licensee for CanSEEK) OINTBiopharma on page 19.
Avacta are top of the list for ‘other FAP-targeted’ agents – item 1, on page 20 with pre|CISION and TMAC.
Overall a good read on the completion and the ’big pharma’ players in this space.
All good.
GLA

And again ...
un 13, 20:30 0.30 -0.03 10,000 TD Securities Inc. TD Securities Inc.
Jun 13, 20:30 0.30 -0.03 9,000 TD Securities Inc. TD Securities Inc.
Jun 13, 20:30 0.30 -0.03 127,000 TD Securities Inc. TD Securities Inc.
GLA

Volume a bit up on average, price down a bit and TD shuffling from one account to another?
https://thecse.com/en/listings/oil-and-gas/canadian-overseas-petroleum-limited
Jun 13, 20:03 0.30 -0.03 123,000 [Buyer] TD Securities Inc. [Seller] TD Securities Inc
Any significance?
GLA

Careers page updated today, not sure what specifically.
https://avacta.com/careers-landing/
Observations (may not be new) …
Wetherby / Diagnostics – email to Avacta, so in-house HR recruiting?
London / Therapeutics – email to vitaresearch, so external agency recruiting?
From the Therapeutics vacancies JD’s …
“Our pre|CISION™ tumour targeted chemotherapy is undergoing clinical trials. This targeted
chemotherapy platform releases active drug only in the tumour, thereby limiting systemic
exposure of potentially toxic anti-cancer treatments.”
Again, ‘bold’ statements, presented as fact?
GLA

Interesting find gadgie.
Have a proper look later, but quick scan ..
Those ‘exquisite’ Affimers again!
"[78] The human FcRn-binding AFFIMER@ polypeptides of the present disclosure include AFFIMER@ polypeptides with exquisite selectivity."
Kind of comparison with TMAC?
"[120] … For example, dual (or multi) mode of action drug conjugates may be conjugated to an anti- FcRn AFFIMER@ polypeptide of the present disclosure. Such dual mode of action drug conjugates include those of the TMAC (Tumor Microenvironment-Activated Conjugates) platform (see, e.g., avacta.com/therapeutics/tmac-affimer-drug-conjugates)."
Aren’t Affimers brilliant (and they're ours).
GLA

Not taking sides, but does look like ‘bold’ statements are permeating the web site, presentations and RNS’s, for example …
https://avacta.com/therapeutics/precision/
“The pre|CISION™ substrate can be utilised in a drug conjugate linker or to generate FAPa-activated chemotherapy – that are only activated in the tumour.”
“When added to a chemotherapy, the pre|CISION™ substrate prevents the drug from entering cells and therefore renders it inert until the substrate is cleaved in the tumour microenvironment.”
Not much in the way of ‘qualification’ here? Not much in the way of might’s, could’s, etc.? No words saying something like … ‘all claims subject to verification by ongoing clinical trials in actual human beings (and, for the avoidance of doubt, not just human tissue grafted onto mice)’?
So quite bold. Let’s hope the ‘words’ have been reviewed for ‘technical merit’ as well as ‘artistic impression’ by someone who actually knows what’s going on.
GLA

@Radika ...
https://www.pacermonitor.com/public/case/42766112/Cuda_Energy_Inc
"Order (I) Approving Asset Purchase and Sale Agreement and Authorizing the Sale of Substantially all of Cuda Energy LLC's Assets Under 11 U.S.C. §§ 363(b) and 363(m); (II) Authorizing the Sale of Assets Free and Clear of All Liens, Claims, Rights, Encumbrances and Other Interests Pursuant to 11 U.S.C. § 363(f); (III) Recognizing and Giving Full Force and Effect to Order(s) of the Canadian Court Approving the Sale of Substantially all Assets and (IV) Granting Related Relief Related [+] (dcsl)"
GLA

Just a few minutes ago ...
https://www.pacermonitor.com/public/case/42766112/Cuda_Energy_Inc
'Signed and sealed'.
GLA

https://webfiles.thecse.com/05_CSE_Form_7_-_Monthly_Progress_Report_-_May_2022.pdf?U1QJOxL_lhV5gfPTVH_.nsieTjnugyTT
May report, don’t think much new?
Item 7. – US Court approval still pending.
Item 17. – Shorter!
US Court and RS Resource Report next week?
GLA

This page updated today …
https://avacta.com/careers-landing/benefits-of-working-at-avacta/
But only vacancy posted has expired?
Were these words there before … “as the Affimer technology develops and moves into the clinic.”?
Or anything else changed?
GLA

‘Laymans’ reading of this …
https://www.pacermonitor.com/public/case/42766112/Cuda_Energy_Inc
19 May – “Withdrawal of Objection to Motion for Entry of Order Approving Sale of Assets … Filed by United States Department of Interior (Peters, Jasmine)”
No objection to our purchase of Cuda assets.
23 May – “Motion to Vacate PENDING SALE HEARING AND FOR ENTRY OF AGREED SALE ORDER APPROVING SALE OF ASSETS … Filed on behalf of FTI Consulting Canda Inc., in its capacity as Receiver by Bradley T Hunsicker. (Hunsicker, Bradley)”
Nothing to talk about, let’s move on.
24 May – “Order Granting Motion To Vacate Pending Sale Hearing and For Entry of Agreed Sale Order Approving Sale of Assets”
Court agrees, let’s move on.
26 May – “BNC Certificate of Mailing - PDF Document … No. of Notices: 3. Notice Date 05/26/2022. (Admin.)”
Paperwork in the post.
GLA

Strange UT (14:00) for 203 @ 118. Bo change to spread.
GLA

Worth checking the latest on Twit for #AVCT from RAH and MMc.
Seems we want to keep AVA6000 to ourselves and not licence?
All good.
GLA

Admit I haven’t looked for a few weeks, and the update is probably just the major investor list, so this (seemingly presented as fact) statement may not be that new …
“The pre|CISION™ targeted chemotherapy platform releases active chemotherapy directly in the tumour, limiting systemic exposure and side effects associated with many commonly used cancer treatments.”
Quite bold (like, it works?).
GLA

https://ecf.wyb.uscourts.gov/calpjm42.pdf
Page 3 item 6.
Total guess, as not a lawyer …
‘Technical’ ‘complaint’ from opposing party – US Dept of Interior, dismissed.
(Stricken – complaint dismissed, Vacated – hearing cancelled)
Well, I hope so.
GLA

Great summary from Tiburn.
Perhaps add (in item 4.) Oil sale / Butane purchase hedges / swaps sorted - just as production about to increase.
Reminder - WTI @ ~USD$110.
GLA

Looks like he moved 100k shares into a SIPP?
If so, would seem prudent given the capital 'appreciation' we are soon likely to see.
GLA

From 12 May RNS …
“In addition, COPL Management will update its shareholders with a presentation via the Investor Meet Company platform to be scheduled following the Q1-22 Results. A separate announcement on this will follow in due course to confirm the date and time, with full details on how to join the virtual presentation.”
Has Katie persuaded Arthur onto Proactive ahead of this?
Start of a ‘news rich’ period for COPL perhaps?
GLA

@Candlestick, re contracts (really need the detail of the actual contracts.
From page 18 of the MD&A …
NGL purchase agreements(1) 1,415 (2022), 4,165 (2023-24), 3,640 (2035-26) (USD$000’s)
(1) Includes commitments to purchase mixed natural gas liquids, consisting primarily of propane and butane for the miscible flood recovery program in the BFU.
Let's hope not (too) binding or an ‘exit’ clause, given we are reducing Butane to zero in favour of Methane?
As noted, done for (to get done) the Atomic deal. As with raises (to get deals done), this is AM 'deal making' pragmatism (or expediency, depending on your outlook). Think now we're coming out of this stage of our evolution - just a bit of 'clearing up' to do!
GLA

Candlestick is correct, just to add …
The arrangement is a ‘Swap’, so 2-way, Oil / Butane. Done for the Atomic deal financing.
Potential for a second arrangement to run from Jan 2023 to Feb 2024 – no wonder we need to be out of this, and so …
from the April Investor Presentation – Item 6, page 10 …
COPL America, Inc.’s current Hedge Program:
– 1,000bbl/d swaps at $56/bbl WTI for 2022 against COPL’s crude oil production *1
– 1.2M gallons/month of Butane (C4) @ MBV La swaps at $0.76/gallon for 2022 to offset COPL’s Butane purchases
• Currently the sales swaps (crude oil) and purchase swaps (C4) offset each other
• COPL is reducing its NGL purchases from 2.2M gallons/month in 2021 to minor to nil volumes in 2022, after switching over to pure Methane (C1) injection at its BFSU miscible flood
*1 Swaps entered into March 15, 2021; 2WTI and Butane as of March 23, 2022
(Methane good, Butane bad).
GLA